MX2012013167A - Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits. - Google Patents

Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits.

Info

Publication number
MX2012013167A
MX2012013167A MX2012013167A MX2012013167A MX2012013167A MX 2012013167 A MX2012013167 A MX 2012013167A MX 2012013167 A MX2012013167 A MX 2012013167A MX 2012013167 A MX2012013167 A MX 2012013167A MX 2012013167 A MX2012013167 A MX 2012013167A
Authority
MX
Mexico
Prior art keywords
derivatives
drug
regulation
inflammatory infiltrate
prevention
Prior art date
Application number
MX2012013167A
Other languages
Spanish (es)
Inventor
Agustin Lugo Radillo
Ivan Delgado Enciso
Alejandrina Rodríguez Hernández
Elpidio Peña Beltran
Original Assignee
Agustin Lugo Radillo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agustin Lugo Radillo filed Critical Agustin Lugo Radillo
Priority to MX2012013167A priority Critical patent/MX2012013167A/en
Priority to PCT/MX2013/000134 priority patent/WO2014073946A2/en
Publication of MX2012013167A publication Critical patent/MX2012013167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of betanidine and its derivatives, betalains and their derivatives, betalamic acid and its derivatives, including the spatial configurations thereof, for the production of a drug for the treatment, prevention, regulation and control of nonalcoholic steatohepatitis, inflammatory infiltrate in liver, hepatic necrosis, fatty liver, alcoholic steatohepatitis, non-alcoholic fatty liver disease, alcoholic fatty liver disease, hepatitis, necrosis, acute inflammatory infiltrate, chronic inflammatory infiltrate, mixed inflammatory infiltrate, non-alcoholic fatty liver, alcoholic fatty liver, liver fibrosis, cirrhosis of the liver, ageing, fibrosis, brain edema, neuronal degeneration and pancreatitis; for the regulation of the mobilisation of intracellular lipids; for the treatment, prevention, regulation and control of inflammatory infiltrate in an autoimmune response, associated with an infection, in tumours, produced as a response to fatty acids and their der ivatives, associated with a trauma, associated with a parasitic disease, associated with chronic degenerative diseases, produced by an immune response to a non-infectious antigen; for the modification of the intracellular lipid composition, for the protection of nucleic acids from damage, for the healing of wounds. Its effect consists in inhibiting the presence of inflammatory infiltrate, inhibiting necrosis and in modifying the predominance of the lipid vesicle type, following administration. The drug can contain one or more betalains and any of their derivatives and betalamic acid and any of its derivatives, either alone or in multiple combinations. In addition, the drug can contain a combination of other pharmaceutical products. The drug can be administered using an administration route. The drug, which contains a betalain, betalamic acid or a derivative of one of these types of compounds and is intended for the treatment, prevention, regulation and control of the above-mentioned a ilments and the regulation and mobilisation of lipids, fatty acids and their derivatives, can be administered to any animal, including humans.
MX2012013167A 2012-11-09 2012-11-09 Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits. MX2012013167A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2012013167A MX2012013167A (en) 2012-11-09 2012-11-09 Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits.
PCT/MX2013/000134 WO2014073946A2 (en) 2012-11-09 2013-11-08 Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012013167A MX2012013167A (en) 2012-11-09 2012-11-09 Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits.

Publications (1)

Publication Number Publication Date
MX2012013167A true MX2012013167A (en) 2014-05-22

Family

ID=50685283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013167A MX2012013167A (en) 2012-11-09 2012-11-09 Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits.

Country Status (2)

Country Link
MX (1) MX2012013167A (en)
WO (1) WO2014073946A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901826A (en) * 2019-12-19 2022-08-12 森正之 Method for synthesizing coronatine II, method for synthesizing betaxanthin, beta-amyloid polymerization inhibitor or Alzheimer's disease therapeutic or preventive agent, amyloid peptide aggregation inhibitor, and HIV-1 protease activity inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119872A (en) * 1996-12-19 2000-01-31 Israel State Pharmaceutical compositions containing antioxidant betalains and a method for their preparation
JP4741206B2 (en) * 2004-07-12 2011-08-03 日本甜菜製糖株式会社 Composition for suppressing or reducing serum cholesterol elevation
DE202005002324U1 (en) * 2005-02-14 2006-06-22 Treusch, Gernot Pharmaceutical composition for the fight against cancer
WO2010014839A1 (en) * 2008-07-30 2010-02-04 Vdf Futureceuticals, Inc. Betalain compositions and uses thereof
ES2349522B1 (en) * 2009-05-05 2011-10-27 Universidad De Murcia PROCEDURE FOR OBTAINING BETALAMIC ACID AND USE OF IT.
LV14588B (en) * 2011-03-30 2012-12-20 Inovatäŗvo Biomedicäŗnas Tehnoloä¢Iju Institåŗts, Sia A composition for prevention of hepatic fatty steatosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901826A (en) * 2019-12-19 2022-08-12 森正之 Method for synthesizing coronatine II, method for synthesizing betaxanthin, beta-amyloid polymerization inhibitor or Alzheimer's disease therapeutic or preventive agent, amyloid peptide aggregation inhibitor, and HIV-1 protease activity inhibitor

Also Published As

Publication number Publication date
WO2014073946A3 (en) 2014-08-07
WO2014073946A2 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
CY1123945T1 (en) IMMEDIATE RELEASE ORAL FORMULATIONS FOR SUBSTITUTED QUINAZOLINONES
EP4332576A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
JP2016511753A5 (en)
RU2018136872A (en) COMPOSITIONS CONTAINING 15-OH EPA AND WAYS OF THEIR APPLICATION
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
WO2015044292A8 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2013183062A3 (en) Palatable formulations of ibuprofen
BR112015011430A2 (en) composition for immediate and prolonged release
CU20140037A7 (en) DERIVATIVES OF ESTRA- 1,3,5 (10), 16- TETRAEN- 3- CARBOXIMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
WO2012021107A8 (en) A liposomal formulation for ocular drug delivery
MX2013009007A (en) High protein nutritional compositions and methods of making and using same.
EA201500112A1 (en) 3-SUBSTITUTED DERIVATIVES ESTRA-1,3,5 (10), 16-TETRAENA, METHODS OF THEIR PRODUCTION, PHARMACEUTICAL MEANS, WHICH CONTAIN THEM, AND THEIR USE FOR RECEPTION OF MEDICINES
MX2020002238A (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states.
IN2014MN01571A (en)
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
WO2017070515A3 (en) Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas)
MX2012013167A (en) Use of betalains and derivatives thereof for the production of a drug for the treatment, prevention, regulation and control of hepatopathies, diseases with inflammatory infiltrate, necrosis and for the modificaiton of lipid deposits.
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
WO2016195194A3 (en) Novel tlr2 antagonists
MX2017013643A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix.